References

  1. Doege KW. FIBRO-SARCOMA OF THE MEDIASTINUM. Ann Surg. Nov 1930;92(5):955-60.
  2. Potter, R.P. Intrathoracic Tumors. Radiology. Jan 1930;14(1):60–1.
  3. Han G, Zhang Z, Shen X, Wang K, Zhao Y, He J. Doege-Potter syndrome: A review of the literature including a new case report. Medicine (Baltimore). July 2017;96(27):e7417-7417.
  4. Chamberlain MH, Taggart DP. Solitary fibrous tumor associated with hypoglycemia: an example of the Doege-Potter syndrome. The Journal of Thorac Cardiovascular Surgery, Jan 2000; 119(1), 185–7.
  5. Lopez‐Hinostroza M, Salazar JM, Dávila J, Absencio AY, Contreras‐Pulache H. Doege–Potter syndrome due to endothoracic solitary hypoglycemic fibrous tumor. Sept 2021.http://dx.doi.org/10.22541/au.163257050.05408155/v1
  6. Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Hormone and IGF Research. Aug 2016;16(14):211-6.
  7. Mohammed T, Ozcan G, Siddique AS, Araneta Iii RN, Slater DE, Khan A. Doege-Potter Syndrome with a Benign Solitary Fibrous Tumor: A Case Report and Literature Review. Case Rep Oncol. Mar 2021;14(1):470–6.
  8. Meng W, Zhu HH, Li H, Wang G, Wei D, Feng X. Solitary fibrous tumors of the pleura with Doege-Potter syndrome: a case report and three-decade review of the literature. BMC Res Notes. Aug 2014;7:515-515.
  9. Denley A, Wallace JC, Cosgrove LJ, Forbes BE. The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 2003;35(11-12):778–85.
  10. de Groot JWB, Rikhof B, van Doorn J, Bilo HJG, Alleman MA, Honkoop AH. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocrine Related Cancer. Dec 2007;14(4):979-93.
  11. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Letters June 2003;195(2):127–37.
  12. Daughaday WH, Kapadia M. Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proceedings of the National Academy of Sciences. Sept 1989;86(17):6778–82.
  13. Frystyk J, Skjærbæk C, Zapf J, Ørskov H. Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia. Diabetologia. Apr 1998;41(5):589–94.
  14. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Seminars in Cell & Developmental Biology, Cancer Cell Metabolism & Notch Signaling. June 2012;23(4):352–61.
  15. Wignall OJ, Moskovic EC, Thway K, Thomas JM. Solitary Fibrous Tumors of the Soft Tissues: Review of the Imaging and Clinical Features With Histopathologic Correlation. American Journal of Roentgenology. July 2010;195(1):W55–W62.
  16. Miraki-Moud F, Grossman AB, Besser M, Monson JP, Camacho-Hübner C. A Rapid Method for Analyzing Serum Pro-Insulin-Like Growth Factor-II in Patients with Non-Islet Cell Tumor Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism, July 2005;90(7):3819–23.
  17. Zapf J, Schmid C, Guler HP, Waldvogel M, Hauri C, Futo E, Hossenlopp P, Binoux M, Froesch ER. Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia. J Clin Invest. Sept 1990;86(3), 952–61.
  18. Jin K, Zhong S, Lin L, Wu J, Wang Y, Cui W. Targeting-intratumoral-lactic-acidosis transcatheter-arterial-chemoembolization for non-islet cell tumor hypoglycemia secondary to a liver metastatic solitary fibrous tumor: A case report and literature review. Front Endocrinol (Lausanne). Aug 2022;13:955687-955687.
  19. Haas RL, Walraven I, Lecointe-Artzner E, Scholten AN, van Houdt WJ, Griffin AM. Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet. International Journal of Radiation Oncology Biology Physics. Aug 2018;101(5):1226-33.
  20. Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. Mar 2014;99(3):713-22.
  21. Ma RCW, Tong PCY, Chan JCN, Cockram CS, Chan MHM. A 67-year-old woman with recurrent hypoglycemia: non-islet cell tumour hypoglycemia. CMAJ. Aug 2005;173(4):359-61.
  22. Demicco EG, Wagner MJ, Maki RG, Gupta V, Iofin I, Lazar AJ. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Mod Pathology. Oct 2017;30(10):1433-42.
  23. Herold G. Innere Medizin 2020 (internet). De Gruyter; 2020. https://books.google.de/books?id=pL3tDwAAQBAJ
  24. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology Oct 2009;27(28):4656-63.
  25. Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci. June 2019;20(12):3049.
  26. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, u. a. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. März 2000;27(3):273–82.
  27. Lococo F, Rufini V, Filice A, Paci M, Rindi G. 68Ga-DOTATOC PET/CT in Pleural Solitary Fibrous Tumors. Clinical Nuclear Medicine. Juni 2021;46(6):e336.